ECSP18094829A - Anticuerpos anti-cd40 y sus usos - Google Patents

Anticuerpos anti-cd40 y sus usos

Info

Publication number
ECSP18094829A
ECSP18094829A ECSENADI201894829A ECDI201894829A ECSP18094829A EC SP18094829 A ECSP18094829 A EC SP18094829A EC SENADI201894829 A ECSENADI201894829 A EC SENADI201894829A EC DI201894829 A ECDI201894829 A EC DI201894829A EC SP18094829 A ECSP18094829 A EC SP18094829A
Authority
EC
Ecuador
Prior art keywords
antibodies
encode
compositions
manufacture
methods
Prior art date
Application number
ECSENADI201894829A
Other languages
English (en)
Inventor
Shiming Ye
Diane San Mu Cohen
Diane Hollenbaugh
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of ECSP18094829A publication Critical patent/ECSP18094829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente divulgación provee nuevos anticuerpos anti-CD40, composiciones que los incluyen, ácidos nucleicos que los codifican, y métodos para su elaboración y su uso.
ECSENADI201894829A 2016-05-27 2018-12-21 Anticuerpos anti-cd40 y sus usos ECSP18094829A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662342417P 2016-05-27 2016-05-27

Publications (1)

Publication Number Publication Date
ECSP18094829A true ECSP18094829A (es) 2019-03-29

Family

ID=59014833

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201894829A ECSP18094829A (es) 2016-05-27 2018-12-21 Anticuerpos anti-cd40 y sus usos

Country Status (34)

Country Link
US (8) US10519243B2 (es)
EP (2) EP3464361B1 (es)
JP (2) JP2019523221A (es)
KR (2) KR102366355B1 (es)
CN (1) CN109476750B (es)
AR (2) AR108611A1 (es)
AU (1) AU2017271602A1 (es)
BR (1) BR112018074468A2 (es)
CA (1) CA3025347A1 (es)
CL (1) CL2018003366A1 (es)
CO (1) CO2018012699A2 (es)
CR (1) CR20180605A (es)
CY (1) CY1124806T1 (es)
DO (1) DOP2018000258A (es)
EC (1) ECSP18094829A (es)
ES (1) ES2901722T3 (es)
HR (1) HRP20211882T1 (es)
HU (1) HUE056670T2 (es)
IL (1) IL263223B2 (es)
LT (1) LT3464361T (es)
MX (1) MX2018014630A (es)
MY (1) MY195442A (es)
NZ (1) NZ748644A (es)
PE (1) PE20190970A1 (es)
PH (1) PH12018502456A1 (es)
PL (1) PL3464361T3 (es)
PT (1) PT3464361T (es)
RS (1) RS62726B1 (es)
RU (1) RU2752049C2 (es)
SG (2) SG10201914132RA (es)
SI (1) SI3464361T1 (es)
TW (2) TWI814279B (es)
UA (1) UA123111C2 (es)
WO (1) WO2017205742A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3097926T3 (da) * 2007-11-01 2019-12-16 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria
JP2019523221A (ja) * 2016-05-27 2019-08-22 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｃｄ４０抗体とその使用
US20210179727A1 (en) * 2018-04-20 2021-06-17 Lyvgen Biopharma Co., Ltd. Anti-cd40 antibodies and uses thereof
KR20210095891A (ko) 2018-11-23 2021-08-03 스트라이크 파마 아베 이중 특이적 접합체
TW202039558A (zh) * 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
CN111454363B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 Cd40抗体及其用途
CN113811547A (zh) 2019-03-27 2021-12-17 国家医疗保健研究所 具有cd40激活特性的重组蛋白
AU2020256828A1 (en) * 2019-04-10 2021-11-18 Nankai University Anti-CD40 antibody and use thereof
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20220332836A1 (en) * 2019-09-11 2022-10-20 Novartis Ag A method for preventing human virus associated disorders in patients
CN115038718A (zh) * 2019-11-08 2022-09-09 先声（上海）医药有限公司 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
US20230242655A1 (en) * 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20230346966A1 (en) * 2020-07-23 2023-11-02 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2024059899A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific polypeptides and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK1135498T3 (da) 1998-11-18 2008-05-26 Genentech Inc Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TW200540186A (en) * 2003-12-25 2005-12-16 Kirin Brewery Mutants of anti-CD40 antibody
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005271892A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
MX2009002414A (es) * 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
NZ585110A (en) * 2007-10-05 2012-09-28 Genentech Inc Method and compositions for diagnosis and treatment of amyloidosis
HUE038788T2 (hu) * 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
EP3508500A1 (en) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
CN104918957B (zh) * 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
CN105143257B (zh) 2013-03-15 2020-10-27 艾伯维生物医疗股份有限公司 Fc变体
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
SG11201702598XA (en) 2014-10-29 2017-05-30 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
HUE048284T2 (hu) * 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
EP3464367B1 (en) * 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
JP2019523221A (ja) * 2016-05-27 2019-08-22 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｃｄ４０抗体とその使用

Also Published As

Publication number Publication date
EP3995511A1 (en) 2022-05-11
CL2018003366A1 (es) 2019-03-15
US20190071509A1 (en) 2019-03-07
US10023645B1 (en) 2018-07-17
US10400041B2 (en) 2019-09-03
SG11201810522UA (en) 2018-12-28
PH12018502456A1 (en) 2019-10-21
TWI814279B (zh) 2023-09-01
US10597460B2 (en) 2020-03-24
US10844131B2 (en) 2020-11-24
MX2018014630A (es) 2019-06-10
US20210277137A1 (en) 2021-09-09
KR20190014524A (ko) 2019-02-12
IL263223A (en) 2018-12-31
EP3464361A1 (en) 2019-04-10
RS62726B1 (sr) 2022-01-31
TW201806971A (zh) 2018-03-01
IL263223B (en) 2022-11-01
US20180186889A1 (en) 2018-07-05
LT3464361T (lt) 2022-01-10
TW202229356A (zh) 2022-08-01
JP2019523221A (ja) 2019-08-22
AR108611A1 (es) 2018-09-05
AU2017271602A1 (en) 2018-12-13
TWI761348B (zh) 2022-04-21
US20170342159A1 (en) 2017-11-30
BR112018074468A2 (pt) 2019-03-06
AR124692A2 (es) 2023-04-26
DOP2018000258A (es) 2019-02-15
US20200040090A1 (en) 2020-02-06
US10519243B2 (en) 2019-12-31
PL3464361T3 (pl) 2022-01-31
HRP20211882T1 (hr) 2022-03-04
NZ748644A (en) 2023-05-26
RU2018146533A (ru) 2020-06-29
JP7331179B2 (ja) 2023-08-22
SG10201914132RA (en) 2020-03-30
US20200010558A1 (en) 2020-01-09
MY195442A (en) 2023-01-21
CY1124806T1 (el) 2022-11-25
US20220119542A1 (en) 2022-04-21
CN109476750A (zh) 2019-03-15
ES2901722T3 (es) 2022-03-23
UA123111C2 (uk) 2021-02-17
KR20220028143A (ko) 2022-03-08
HUE056670T2 (hu) 2022-02-28
KR102366355B1 (ko) 2022-02-24
CA3025347A1 (en) 2017-11-30
SI3464361T1 (sl) 2022-01-31
JP2022068294A (ja) 2022-05-09
RU2752049C2 (ru) 2021-07-22
PT3464361T (pt) 2021-12-27
US20210024642A1 (en) 2021-01-28
CN109476750B (zh) 2022-02-01
CR20180605A (es) 2020-01-13
RU2018146533A3 (es) 2020-06-29
CO2018012699A2 (es) 2019-08-20
PE20190970A1 (es) 2019-07-09
WO2017205742A1 (en) 2017-11-30
IL263223B2 (en) 2023-03-01
EP3464361B1 (en) 2021-11-10

Similar Documents

Publication Publication Date Title
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CO2020006900A2 (es) Medios y método para preparar vectores virales y usos de los mismos
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
AR105634A1 (es) Anticuerpos que se unen a il 8 y sus usos
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
CL2017001461A1 (es) Composiciones y métodos para anticuerpos que se marcan bmp6
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
CO2017011546A2 (es) Adhesivos acrílicos en emulsión
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso
CL2019000500A1 (es) Compuestos que contienen monoterpenoide/fenilpropanoide, sus métodos de elaboración y su uso como herbicida.
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos